Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
LY2801653
114
CHF
CHF 114.00
In stock
SYN-1222-M0011 mgCHF 114.00
SYN-1222-M0055 mgCHF 255.00
SYN-1222-M01010 mgCHF 383.00
SYN-1222-M05050 mgCHF 1'064.00
SYN-1222-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | LY-2801653; N-(3-Fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide |
| Product Type | Chemical |
| Properties | |
| Formula | C30H22F2N6O3 |
| MW | 552.5 |
| CAS | 1206799-15-6 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: c-MET | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | QHADVLVFMKEIIP-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R and other oncoproteins. It displays anti-tumour activities in mouse xenograft models. In vitro, LY2801653 has an IC50 for inhibition of MET phosphorylation between 35.2-59.2nM. LY2801653 was found in nonclinical models to also have potent activity against several other receptor tyrosine oncokinases including FLT3, AXL, MERTK, TEK, ROS1, DDR1/2 and against the serine/threonine kinases MKNK1/2.
Product References
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models: S.B. Yan, et al.; Invest. New Drugs. 31, 833 (2013)
Related Products
